TRIM31 promotes glioma proliferation and invasion through activating NF-κB pathway
Received 12 August 2018
Accepted for publication 10 December 2018
Published 27 March 2019 Volume 2019:12 Pages 2289—2297
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Federico Perche
Li Zhou,1 Zhe-Zhi Deng,2 Hai-Yan Li,2 Nan Jiang,3 Zhi-Sheng Wei,4 Ming-Fan Hong,4 Xiao-Dang Chen,2 Ji-Hui Wang,2 Ming-Xing Zhang,1 Yi-Hua Shi,1 Zheng-Qi Lu,1,2 Xu-Ming Huang1
1Department of Rehabilitation, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China; 2Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; 3Department of Hepatic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; 4Department of Neurology, The First Affiliated Hospital of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou 510080, China
Background: Glioma is the most lethal primary brain tumor, the survival rate still isn’t improved in the past decades. It’s essential to study the regulatory mechanism of glioma progression, hoping to find new therapy targets or methods. The family of tripartite motif (TRIM) containing proteins are E3 ubiquitination ligases, which play critical role in various tumor progression.
Methods: Cell proliferation and invasion were analyzed by colony formation assay, soft agar growth assay, BrdU incorporation assay and transwell invasion assay. Luciferase reporter analysis was used to analyze NF-κB pathway activity.
Results: We found TRIM31 was upregulated in glioma cells and tissues, its overexpression significantly promoted glioma cell proliferation and invasion, while its knockdown significantly inhibited glioma cell proliferation and invasion. Mechanism analysis found TRIM31 promoted NF-κB pathway activity and increased its targets expression. NF-κB inhibition reversed the phenotype caused by TRIM31, confirming TRIM31 promoted glioma progression through activating NF-κB pathway. Using clinical specimens found TRIM31 expression was positively correlative with NF-κB activity.
Conclusion: This study found TRIM31 promoted glioma proliferation and invasion through activating NF-κB activity.
Keywords: TRIM31, glioma, NF-κB, proliferation, invasion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]